CBG: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
Visual
No edit summary
No edit summary
 
Line 1: Line 1:
{{TreatmentInfo
{{TreatmentInfo
|drug_name=Cannabigerol (CBG)
|drug_name=Sativex (Nabiximols)
|overview=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, is currently under investigation for its potential anti-cancer properties. Although not FDA-approved, preclinical studies have explored CBG's ability to induce apoptosis, inhibit cell proliferation, and target cancer stem cells, highlighting its promise in cancer research. While cannabinoids, including CBG, are generally regarded as safe, specific studies on its side effects remain limited, and detailed human clinical trials are needed to confirm its safety and efficacy. Ongoing research aims to determine its potential role in cancer treatment, particularly its impact on tumor progression and pathways involved in cancer development.
|FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis
|FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition)
|used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management
|used_for=Investigational use in cancer research for potential anti-tumor effects
|clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma
|clinical_trial_phase=Preclinical studies and early research
|common_side_effects=Fatigue, dizziness, nausea, mouth irritation
|common_side_effects=Not specifically documented; cannabinoids are generally considered to have a favorable safety profile, but specific studies on CBG's side effects are limited
|OS_with=The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone
|OS_with=Not applicable; research is still in preclinical stages, focusing on cellular and animal models
|PFS_with=Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival
|PFS_with=Not applicable; ongoing studies aim to determine the potential impacts on tumor progression
|usefulness_rating=4
|usefulness_rating=3
|notes=In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.
|notes=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, has garnered attention in preclinical studies for its potential anti-cancer properties. Research has explored CBG's effects on various cancer cell lines, including its ability to induce apoptosis, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully establish its efficacy and optimal use in cancer treatment.
|treatment_category=Investigational Drugs
|treatment_category=Nutraceuticals
|links=
|links=
|toxicity_level=2
|toxicity_level=2
|toxicity_explanation=Cannabigerol (CBG) is generally considered safe, as it's a non-psychoactive compound found in the cannabis plant. However, specific studies on CBG’s side effects are limited owing to the fact that it is in the early stages of research. Therefore, a rating of 2 is given, indicating a low level of potential toxicity. However, definitive conclusions about its toxicity can only be made after detailed human clinical trials have been conducted.
|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.
}}
|overview=Sativex (Nabiximols) is an investigational drug not approved by the FDA in the United States but used in several countries to manage spasticity in multiple sclerosis and is being studied for its potential benefits in glioblastoma treatment. A 2021 Phase 2 clinical trial showed promising results, indicating an increase in overall survival when Sativex was used alongside temozolomide, although more research is needed to fully understand its effects and safety.}}

Latest revision as of 01:19, 18 January 2025

Property Information
Drug Name Sativex (Nabiximols)
Overview Sativex (Nabiximols) is an investigational drug not approved by the FDA in the United States but used in several countries to manage spasticity in multiple sclerosis and is being studied for its potential benefits in glioblastoma treatment. A 2021 Phase 2 clinical trial showed promising results, indicating an increase in overall survival when Sativex was used alongside temozolomide, although more research is needed to fully understand its effects and safety.
FDA Approval Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis
Used for Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management
Clinical Trial Phase Phase 2 clinical trial in 2021 indicated for glioblastoma
Clinical Trial Explanation Not specified
Common Side Effects Fatigue, dizziness, nausea, mouth irritation
OS without Not specified
OS with The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone
PFS without Not specified
PFS with Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.

Notes: In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.


From Ben Williams Book: Not specified


You are not allowed to post comments.
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=CBG&oldid=94190"